Cellectis Analyst Ratings
Cellectis Analyst Ratings
JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cellectis SA (CLLS) and Sanofi (OtherSNYNF)
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Fortrea Holdings Inc. (FTRE) and Cellectis SA (CLLS)
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Cellectis SA: Strong Investment and Clinical Progress Signaling a Market Outperform Rating
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
Barclays Remains a Buy on Cellectis SA (CLLS)
Cellectis SA: A Hold Rating Amidst Strategic Partnerships and Pipeline Potential
Hold Rating for Cellectis SA: A Balance of Promising Data and Pending Uncertainties
Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)
JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target
Cellectis Analyst Ratings
JonesTrading Sticks to Their Hold Rating for Cellectis SA (CLLS)
Oppenheimer Reiterates Outperform on Cellectis, Maintains $11 Price Target
Cellectis Analyst Ratings
JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target
Cellectis Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cellectis SA (CLLS), Globus Medical (GMED) and Blueprint Medicines (BPMC)